Profusa, Inc. (PFSA): Entry into a Material Definitive Agreement
Profusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed, the Company is party to a Securities Purchase Agreement, dated as of February 11, 2025 (as amended, the “Purchase Agreement”), by and among the Company, Ascent Partners Fund LLC, a Delaware limited lia
How this was made
The 30-second read
Why it matters
The note adds $769k of senior secured debt and convertible equity potential, which may dilute existing shareholders and increase leverage.
Market read
A primary disclosure of a financing instrument that could affect PFSA's share price through dilution and debt considerations.
What to watch
Potential for the note to be prepaid after a subsequent equity offering, reducing dilution risk.
Background
Profusa Inc. (NASDAQ: PFSA) is a micro‑cap biotech developing diagnostic technologies. The filing details a financing transaction with Ascent Partners Fund.
Ticker impact
Profusa filed an 8‑K reporting issuance of a $769,230 senior secured convertible note with a $4.28 conversion price.
downward pressure as investors price in dilution risk and higher leverage
New debt and conversion rights increase share supply; interest rate and default provisions add risk.
Market effects
Limited to biotech financing trends; may signal increased use of convertible notes for capital raises.
Primarily affects US micro‑cap biotech investors.
Low; no broader market impact.
Counterpoint
If the note converts at a floor price above current levels, it could provide upside for shareholders.
Key entities
- companyProfusa, Inc.
Issuer of the convertible note.
- investorAscent Partners Fund LLC
Purchaser and collateral agent for the note.